Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 20/20 | 0.63 |
| ▸ | PDCD1 | Q15116 | 13/20 | 0.63 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20763744 | 0.86 | CD274 (0.66) | CD274PDCD1 | |
| SCHEMBL23949242 | 0.86 | CD274 (0.66) | CD274PDCD1 | |
| SCHEMBL20763893 | 0.85 | CD274 (0.61) | CD274PDCD1 | |
| SCHEMBL22132101 | 0.84 | CD274 (0.68) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL23949302 | 0.84 | CD274 (0.56) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL20539957 | 0.84 | CD274 (0.56) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL20764129 | 0.84 | CD274 (0.60) | CD274PDCD1 | |
| SCHEMBL23949432 | 0.83 | CD274 (0.68) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL23949435 | 0.83 | CD274 (0.68) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL20539919 | 0.83 | CD274 (0.68) | CD274PDCD1PDCD1LG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787766-B2 | Compound having PD-L1 inhibitory activity, preparation method therefor and use thereof | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2023-10-17 | — | — | US | disclosed |
| US-11787766-B2 | Compound having PD-L1 inhibitory activity, preparation method therefor and use thereof | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2023-10-17 | — | — | US | disclosed |
| US-20200392083-A1 | COMPOUND HAVING PD-L1 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2020-12-17 | — | — | US | disclosed |
| EP-3669872-A1 | COMPOUND HAVING PD-L1 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019034172-A1 | COMPOUND HAVING PD-L1 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海轶诺药业有限公司 | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392083-A1 | COMPOUND HAVING PD-L1 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | CD274, PDCD1LG2, PDCD1 | CD274 1/4885PDCD1 3/4885PDCD1LG2 2/4885 |
| US-11787766-B2 | Compound having PD-L1 inhibitory activity, preparation method therefor and use thereof | CD274, PDCD1, PDCD1LG2 | CD274 1/4885PDCD1 2/4885PDCD1LG2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.